BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3437781)

  • 1. Deamination rates of 1-beta-D-arabinofuranosylcytosine, deoxycytidine and 5-methyl-2'-deoxycytidine in seven hematopoietic cell lines.
    Jekunen A
    Med Biol; 1987; 65(4):203-8. PubMed ID: 3437781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alkylated cytosine nucleosides: substrate and inhibitor properties in enzymatic deamination.
    Krajewska E; Shugar D
    Acta Biochim Pol; 1975; 22(2):185-94. PubMed ID: 1098340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells.
    Wan CW; Mak TW
    Cancer Res; 1978 Sep; 38(9):2768-72. PubMed ID: 679182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of deamination-related cytotoxicity of 5-methyl-2'-deoxycytidine by tetrahydrouridine in human leukemia cells.
    Jekunen A; Vilpo JA
    J Natl Cancer Inst; 1984 Nov; 73(5):1087-91. PubMed ID: 6593484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiles of pyrimidine biosynthesis, salvage and degradation in disks of potato (Solanum tuberosum L.) tubers.
    Katahira R; Ashihara H
    Planta; 2002 Sep; 215(5):821-8. PubMed ID: 12244448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
    Chabot GG; Bouchard J; Momparler RL
    Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
    Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
    Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low cytidine deaminase levels in human hematopoietic cell lines.
    Nygaard P; Sundström C
    Leuk Res; 1987; 11(8):681-5. PubMed ID: 3626611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
    Niitsu N; Ishii Y; Matsuda A; Honma Y
    Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Methyl-2'-deoxycytidine. Metabolism and effects on cell lethality studied with human leukemic cells in vitro.
    Jekunen A; Vilpo JA
    Mol Pharmacol; 1984 May; 25(3):431-5. PubMed ID: 6587184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells.
    Ohta T; Hori H; Ogawa M; Miyahara M; Kawasaki H; Taniguchi N; Komada Y
    Oncol Rep; 2004 Nov; 12(5):1115-20. PubMed ID: 15492802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells.
    Momparler RL; Eliopoulos N; Bovenzi V; LĂ©tourneau S; Greenbaum M; Cournoyer D
    Cancer Gene Ther; 1996; 3(5):331-8. PubMed ID: 8894252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic studies on possible improvement of cytosine arabinoside treatment.
    Mejer J
    Scand J Clin Lab Invest; 1981 Feb; 41(1):29-34. PubMed ID: 6942484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
    Mekras JA; Boothman DA; Greer SB
    Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the role of cytidine deaminase in cellular metabolism.
    Nygaard P
    Adv Exp Med Biol; 1986; 195 Pt B():415-20. PubMed ID: 3532704
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of hydroxyurea and thymidine derivatives on the uptake and metabolism of deoxycytidine and arabinofuranosylcytosine in log phase and contact-inhibited human diploid fibroblasts.
    Snyder RD; Malick NC
    Mol Pharmacol; 1985 Dec; 28(6):574-80. PubMed ID: 4079913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and substrate specificity of human and canine cytidine deaminase.
    Fanucchi MP; Watanabe KA; Fox JJ; Chou TC
    Biochem Pharmacol; 1986 Apr; 35(7):1199-201. PubMed ID: 3964296
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture.
    Boothman DA; Briggle TV; Greer S
    Mol Pharmacol; 1985 May; 27(5):584-94. PubMed ID: 2581125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
    Matsushita T; Ryu EK; Hong CI; MacCoss M
    Cancer Res; 1981 Jul; 41(7):2707-13. PubMed ID: 7248939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.